TGTX (TG Therapeutics) Moat Score: 3/10 (As of Jul. 05, 2026)


TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $53.31
GF Value $58.75
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Moat Score?

TG Therapeutics TGTX -0.39% 82 Moat Score is 3 as of Jul. 05, 2026. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $58.75 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,395 Biotechnology companies, TG Therapeutics ranks better than 75.48% on this metric.

TG Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

TG Therapeutics has No Moat: TG Therapeutics Inc has limited market leadership and lacks significant customer switching costs or strong brand loyalty. The biotech industry is highly competitive, and while they may have some intellectual property, it is not enough to establish a durable competitive advantage. The company does not exhibit significant regulatory barriers or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes TG Therapeutics might have No Moat - Very weak/transient advantages.

TG Therapeutics  (NAS:TGTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

TG Therapeutics Moat Score Related Terms

TGTX vs HALO, KYMR, PCVX: Moat Score Comparison

For the Biotechnology subindustry, TG Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Moat Score falls into.


TGTX
82GF Score
TG Therapeutics Inc TGTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
TG Therapeutics (TGTX) has a Moat Score of 3 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, TG Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, placing it in the top 24.5%.
Is TG Therapeutics' Moat Score too high?
TG Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. TG Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, TG Therapeutics ranks #342 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Moat Score compare to HALO and KYMR?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #342 out of 1395 companies for Moat Score. This places TG Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. TG Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TG Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $58.75, compared to a current price of $53.31 — trading 9.3% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current Moat Score is 3 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $53.31 is trading 9.3% below its estimated GF Value™ of $58.75. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • Moat Score: 3
  • GF Value™: $58.75 vs. price of $53.31 (9.3% below fair value)
  • GF Score™: 82/100 with 8 warning signs
  • Industry Position: 50% above the Biotechnology median (#342 of 1395)

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.31
Price
$58.75
GF Value